Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study

Current Medical Research and Opinion

Volumn 25, Issue 10, 2009, Pages 2361-2371

  Pratley, Richard E ^a   Reusch, Jane E B ^b   Fleck, Penny R ^c   Wilson, Craig A ^c   Mekki, Qais ^c  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Alogliptin; Dipeptidyl peptidase 4 inhibitor; Glycemic control; Thiazolidinedione; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; GLIBENCLAMIDE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY WEIGHT; CALCIUM BLOOD LEVEL; CELLULITIS; CLINICAL TRIAL; COLON CANCER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DERMATITIS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; INCIDENCE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PIPERIDINES; PLACEBOS; THIAZOLIDINEDIONES; URACIL; YOUNG ADULT;

EID: 70349314675     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903156111     Document Type: Article

References (21)

1. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001;104:517-529 (Pubitemid 32201947)
2. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-1972
3. Resnick HE, Foster GL, Bardsley J, et al. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002, the National Health and Nutrition Examination Survey. Diabetes Care 2006;29:531-537
4. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31:173-175
5. Berger J, Bailey P, Biswas C, et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996;137:4189-4195 (Pubitemid 26321865)
6. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118
7. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
8. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206 (Pubitemid 47057766)
9. Zinman B, Hoogwerf BJ, Durán García S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007;146:477-485 (Pubitemid 351650556)
10. Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007;50:2297-2300 (Pubitemid 46799241)
11. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of multiple oral doses of the dipeptidyl peptidase-4 inhibitor alogliptin benzoate in patients with type 2 diabetes. Clin Ther 2008;30:499-512
12. Moritoh Y, Takeuchi K, Kataoka O, et al. Pharmacological effects of combination treatment with alogliptin, a novel, highly selective dipeptidyl peptidase-IV inhibitor, and pioglitazone on glycemic control in ob/ob mice. Eur J Pharmacol 2009;602:448-454
13. Karim A, Fleck P, Joseph M, et al. No pharmacokinetic interaction between alogliptin benzoate (SYR-322) and pioglitazone hydrochloride [abstract]. Diabetes 2007;56:A536
14. Fleck P, Christopher R, Covington P, et al. Efficacy and safety of alogliptin monotherapy over 12 weeks in patients with type 2 diabetes [abstract]. Diabetes 2008;57:A143
15. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166-174 (Pubitemid 46206560)
16. Rosenstock J, Brazg R, Andryuk PJ, et al.; and Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-1568
17. Rosenstock J, Baron MA, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175-185 (Pubitemid 46206561)
18. Bloomgarden ZT, Dodis R, Viscoli CM, et al. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006;29:2137-2139 (Pubitemid 44871202)
19. European public assessment report for Galvus - scientific discussion. European Medicines Agency. Available at: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/galvus/H-771-en6.pdf [Last accessed 28 July 2008]
20. Pratley R, Kipnes M, Fleck P, et al.; on behalf of the Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase- 4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009;11:167-176
21. Defronzo RA, Fleck PR, Wilson CA, et al.; on behalf of the Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes mellitus and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008;31:2315-2317